[video/transcript]Sarepta Therapeutics Could Be Onto Something Big

[video/transcript]Sarepta Therapeutics Could Be Onto Something Big

Source: 
Motley Fool
snippet: 

Last week, Sarepta Therapeutics (NASDAQ:SRPT) unveiled early stage data from trials evaluating a gene therapy for Duchenne muscular dystrophy, and the results were really impressive. Based on increases in micro-dystrophin production and decreases in markers of muscle damage, the company's plan to insert a gene in patients that produces dystrophin may help over half of those diagnosed with this devastating disease.